The efflux pump SmeDEF contributes to trimethoprim-sulfamethoxazole resistance in Stenotrophomonas maltophilia

Antimicrob Agents Chemother. 2015 Jul;59(7):4347-8. doi: 10.1128/AAC.00714-15. Epub 2015 Apr 27.

Abstract

Trimethoprim-sulfamethoxazole (co-trimoxazole) is one of the antimicrobials of choice for the treatment of Stenotrophomonas maltophilia infections. The analysis of mutants either lacking or overexpressing the efflux pump SmeDEF shows that this efflux pump contributes to intrinsic and acquired co-trimoxazole resistance in S. maltophilia. Since SmeDEF can extrude a variety of antibiotics, selection with such antimicrobials, including quinolones, might also select for S. maltophilia co-trimoxazole resistance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Bacterial Proteins / genetics*
  • Bacterial Proteins / metabolism*
  • Drug Resistance, Bacterial / genetics*
  • Membrane Transport Proteins / genetics*
  • Membrane Transport Proteins / metabolism*
  • Microbial Sensitivity Tests
  • Mutation / genetics
  • Quinolones / pharmacology
  • Stenotrophomonas maltophilia / drug effects*
  • Stenotrophomonas maltophilia / genetics
  • Stenotrophomonas maltophilia / metabolism
  • Trimethoprim, Sulfamethoxazole Drug Combination / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Membrane Transport Proteins
  • Quinolones
  • Trimethoprim, Sulfamethoxazole Drug Combination